Literature DB >> 12213685

APOE epsilon4 and low cholesterol as risks for depression in a biracial elderly community sample.

Dan G Blazer1, Bruce B Burchett, Gerda G Fillenbaum.   

Abstract

OBJECTIVE: The epsilon4 allele of apolipoprotein (APOE) is known to be associated with a number of adverse health outcomes, yet the association of the allele with depression has not been conclusively determined. The authors explored the hypothesis that the epsilon4 allele is a risk factor for depression among older persons with a low cholesterol level (a known risk factor for depression).
METHODS: A biracial community sample of 2,550 older African Americans and Whites in North Carolina was genotyped for APOE, tested for cholesterol, and evaluated for depression at both baseline and 4-year follow-up.
RESULTS: No relationship was found between the epsilon4 allele and depression or low cholesterol and depression in either cross-sectional or longitudinal analyses. The interaction of the epsilon4 allele and cholesterol was also not associated with depression in controlled analyses. Female gender, less education, being unmarried, and cognitive impairment were associated with depression in cross-sectional controlled analyses; only cognitive impairment was associated with depression in longitudinal analyses.
CONCLUSION: Despite the association of the epsilon4 allele with a number of adverse health outcomes, as well as the association between depression and cholesterol in previous studies, no association was found between epsilon4 and low cholesterol or depression in cross-sectional and longitudinal analyses. The interaction of epsilon4 and cholesterol was not associated with depression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213685

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  8 in total

1.  Lipid trajectories as predictors of depressive symptoms: the Young Finns Study.

Authors:  Marko Elovainio; Laura Pulkki-Råback; Mika Kivimäki; Markus Jokela; Jorma Viikari; Olli T Raitakari; Risto Telama; Liisa Keltikangas-Järvinen
Journal:  Health Psychol       Date:  2010-05       Impact factor: 4.267

2.  Depressive symptoms moderate the influence of the apolipoproteine epsilon4 allele on cognitive decline in a sample of community dwelling older adults.

Authors:  Elizabeth A Corsentino; Kathryn Sawyer; Natalie Sachs-Ericsson; Dan G Blazer
Journal:  Am J Geriatr Psychiatry       Date:  2009-02       Impact factor: 4.105

3.  Depression in vascular pathologies: the neurologist's point of view.

Authors:  Rita Moretti; Elena Bernobich; Francesca Esposito; Paola Torre; Rodolfo M Antonello; Luisa De Angelis; Giuseppe Bellini
Journal:  Vasc Health Risk Manag       Date:  2011-07-12

4.  Total serum cholesterol, atherogenic indices and their longitudinal association with depressive symptoms among US adults.

Authors:  M A Beydoun; H A Beydoun; G A Dore; M T Fanelli-Kuczmarski; M K Evans; A B Zonderman
Journal:  Transl Psychiatry       Date:  2015-03-03       Impact factor: 6.222

5.  Role of apolipoprotein E epsilon 4 (APOE*ε4) as an independent risk factor for incident depression over a 12-year period in cognitively intact adults across the lifespan.

Authors:  Richard Andrew Burns; Shea Andrews; Nicolas Cherbuin; Kaarin Jane Anstey
Journal:  BJPsych Open       Date:  2020-05-08

6.  Association between tea consumption and depressive symptom among Chinese older adults.

Authors:  Ke Shen; Bin Zhang; Qiushi Feng
Journal:  BMC Geriatr       Date:  2019-09-04       Impact factor: 3.921

7.  Genetic testing for Alzheimer's and long-term care insurance.

Authors:  Donald H Taylor; Robert M Cook-Deegan; Susan Hiraki; J Scott Roberts; Dan G Blazer; Robert C Green
Journal:  Health Aff (Millwood)       Date:  2010 Jan-Feb       Impact factor: 9.048

Review 8.  The potential applications of Apolipoprotein E in personalized medicine.

Authors:  Sylvia Villeneuve; Diane Brisson; Natalie L Marchant; Daniel Gaudet
Journal:  Front Aging Neurosci       Date:  2014-07-08       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.